Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DSG2
REST API REST API
Homo sapiens
DSG2 is differentially expressed in 287 experiments: 169 organism parts: prostate, salivary gland, ... (167 more);, 249 disease states: normal, glioblastoma, ... (247 more);, 103 cell types 533 cell lines 42 compound treatments and 71 other conditions.
Synonyms CDHF5
Orthologs CABZ01055869.1 (Danio rerio)   Dsg2 (Mus musculus)   F1NJD5_CHICK (Gallus gallus)   DSG2 (Bos taurus)   FP236168.1 (Danio rerio)   si:ch73-74h11.1 (Danio rerio)   Dsg2 (Rattus norvegicus)   DSG2 (Xenopus laevis)   DSG2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, apoptosis, cell-cell junction, membrane, homophilic cell adhesion, cell adhesion, integral to membrane, calcium ion binding, desmosome, cellular component disassembly involved in apoptosis
InterPro Term Cadherin, Cadherin_cytoplasmic-dom, Desmo_cadherin, Desmoglein
UniProt Accession Q14126
Gene-Disease Assocation ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 10; ARVD10, CARDIOMYOPATHY, DILATED, 1BB; CMD1BB
Search EB-eye ENSG00000046604
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
SW480
3
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
HCC38
2
E-MTAB-37, E-MTAB-62
HepG2
2
E-MTAB-37, E-GEOD-7307
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-10A
2
E-TABM-420, E-GEOD-14990
527 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (51 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-18147, E-GEOD-20033, E-GEOD-18265
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
endothelial cell
1
2
E-GEOD-3920, E-GEOD-19240, E-GEOD-3998
epithelial cell
1
2
E-MEXP-2034, E-GEOD-4483, E-GEOD-10797
macrophage
1
E-GEOD-22373
97 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, E-TABM-15, ... (52 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-6014, E-GEOD-4290, E-MTAB-62, E-GEOD-4412
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
prostate carcinoma
4
E-MTAB-62, E-MEXP-2034, E-MTAB-37, E-GEOD-7307
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-3726
colorectal carcinoma
2
E-MTAB-37, E-GEOD-23878
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
243 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (26 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
none
4
5
E-GEOD-5824, E-GEOD-5099, E-MEXP-1958, E-MEXP-1230, E-GEOD-412, ... (9 experiments)
pegylated granulocyte colony stimulating factor
1
E-GEOD-4688
keratinocyte growth factor
1
E-GEOD-7216
resveratrol
1
E-TABM-782
CNOT7+CNOT8
1
1
E-MEXP-2218
36 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
56
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-6710, E-GEOD-19348, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-2509, E-GEOD-22148, E-TABM-147, ... (7 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-TABM-36, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-GEOD-2292, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-12773, E-TABM-127, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2657, E-GEOD-1926, E-MEXP-2069, ... (30 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-980, E-GEOD-17400

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-21750, E-GEOD-1460, E-GEOD-17636

Population
studied in E-GEOD-4922

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922, E-TABM-147

Tumor size
studied in E-GEOD-6532

Processing time: 0.305 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM